

BIOWORLD™ TODAY

THE DAILY BIOPHARMACEUTICAL NEWS SOURCE

July 15, 2016

Beyondspring Pharmaceuticals Inc., of New York, said the FDA notified the company that the phase I/II study with Opdivo (nivolumab, Bristol-Myers Squibb Co.) in combination with plinabulin for patients with metastatic non-small-cell lung cancer may proceed with enrolling patients. The smallmolecule immuno-oncology agent plinabulin activates dendritic cell maturation, induces tumor antigen-specific T-cell activation and down-regulates Treg. Opdivo is a PD-1 inhibitor.